Compare FDMT & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDMT | BVS |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 783.2M |
| IPO Year | 2019 | 2016 |
| Metric | FDMT | BVS |
|---|---|---|
| Price | $11.10 | $13.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $31.71 | $14.00 |
| AVG Volume (30 Days) | 581.3K | ★ 810.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.79 | ★ 163.46 |
| EPS | N/A | ★ 0.52 |
| Revenue | $85,209,000.00 | ★ $568,087,000.00 |
| Revenue This Year | N/A | $7.52 |
| Revenue Next Year | $70.28 | $7.06 |
| P/E Ratio | ★ N/A | $27.16 |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $5.46 | $6.26 |
| 52 Week High | $14.00 | $15.89 |
| Indicator | FDMT | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 62.18 |
| Support Level | $9.63 | $7.20 |
| Resistance Level | $11.89 | N/A |
| Average True Range (ATR) | 0.58 | 0.79 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 86.27 | 55.20 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.